Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 33

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 1
Chunk 33
---
udited
condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing
losses from operations and at December 31, 2024 had limited working capital and an accumulated deficit of $161,699,924. These factors,
among other matters, raise substantial doubt about our ability to continue as a going concern within one year of the date of the financial
statements included in this Quarterly Report. A significant amount of additional capital will be necessary to advance the development
of our products to the point at which they may become commercially viable. We intend to fund operations, working capital and other cash
requirements for the twelve-month period subsequent to December 31, 2024 through a combination of debt and/or equity financing arrangements
and potentially from collaborations or strategic partnerships.

 24 

The successful outcome
of future activities cannot be determined at this time and there is no assurance that, if achieved, we will have sufficient funds to execute
our intended business plan or generate positive operating results.

The condensed consolidated
financial statements do not include any adjustments related to this uncertainty and as to the recoverability and classification of asset
carrying amounts or the amount and classification of liabilities that might result should we be unable to continue as a going concern.

May 2024 Public Offering

On May 17, 2024, we closed a public offering pursuant
to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000
shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of
$0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common
stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000
shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal
to the public offering price per share of common stock and accompanying warrants, less the $0.001 per share exercise price of each such
pre-funded warrant.

All pre-funded warrants issued in the